Emerging drugs for nosocomial pneumonia

References

• American Thoracic Society. Infectious Diseases Society of American Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002 Dec;122(6):2115–2121.
   PubMed Web of Science ®Google Scholar
• Koulenti D, Lisboa T, Brun-Buisson C, et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med. 2009;37:2360–2368.
   PubMed Web of Science ®Google Scholar
• Dudeck MA, Horan TC, Peterson KD, et al. National Healthcare Safety Network (NHSN) report, data summary for 2010, device-associated module. Am J Infect Control. 2011;39(10):798–816.
   PubMed Web of Science ®Google Scholar
• Valles J, Pobo A, Garcia-Esquirol O, et al. Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset. Intensive Care Med. 2007;33(8):1363–1368.
   PubMed Web of Science ®Google Scholar
• Melsen WG, Rovers MM, Groenwold RHH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomized prevention studies. Lancet Infect Dis. 2013 Aug;13(8):665–671.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Kollef MH, Hall JB. Risk factors for ventilator-associated pneumonia: from epidemiology to patient management. Clin Infect Dis. 2004;38:1141–1149.
   PubMed Web of Science ®Google Scholar
• Siempos II, Vardakas KZ, Kyriakopoulos CE, et al. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock. 2010 Jun;33(6):590–601.
   PubMed Web of Science ®Google Scholar
• Borgatta B, Rello J. How to approach and treat VAP in ICU patients. BMC Infect Dis. 2014 Apr 30;14:211.
   PubMed Web of Science ®Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14.
   PubMed Web of Science ®Google Scholar
• Micek S, Johnson MT, Reichley R, et al. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis. 2012;12:56.
   PubMed Web of Science ®Google Scholar
• Tedja R, Nowacki A, Fraser T, et al. The impact of multidrug resistance on outcomes in ventilator-associated pneumonia. Am J Infect Control. 2014;42(5):542–545.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect. 2015 Mar;70(3):213–222.
   PubMed Web of Science ®Google Scholar
• Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J. 2008 Mar;31(3):625–632.
   PubMed Web of Science ®Google Scholar
• Bailey KL, Kalil AC. Ventilator-associated pneumonia (VAP) with multidrug-resistant (MDR) pathogens: optimal treatment? Curr Infect Dis Rep. 2015 Aug;17(8):494.
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis. 2010;50:364–373.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in US and European hospitals: results from the SENTRY antimicrobial surveillance program, 2009–2012. Int J Antimicrob Agents. 2014 Apr;43(4):328–334.
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Jones RN, Fritsche TR, et al. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the sentry antimicrobial surveillance program (2000–2004). Microb Drug Resist 2006, 12:223–230.
   PubMed Web of Science ®Google Scholar
• EARSS. European Antimicrobial Resistance Surveillance System; Annual Report. 2008. [cited 2010 Nov]. Availablefrom: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Documents/2008_EARSS_Annual_Report.pdf
   Google Scholar
• Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis. 2014;58(Suppl 1):S20–7.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621–629.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Ginocchio F, Giacobbe DR. New approaches for empiric therapy in Gram-positive sepsis. Minerva Anestesiol. 2011 Aug;77(8):821–827. Review.
   PubMed Web of Science ®Google Scholar
• Rello J, Ulldemolins M, Lisboa T, et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. EurRespirJ. 2011;37:1332– 1339.
   PubMed Web of Science ®Google Scholar
• Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014 Jan;43(1):52–59.
   PubMed Web of Science ®Google Scholar
• Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect. 2012;18(1):4–7.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879–884.
   PubMed Web of Science ®Google Scholar
• Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis. 2010;51:1238–1244.
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65(6):1119–1125.
   PubMed Web of Science ®Google Scholar
• Liapikou A, Rosales-Mayor E, Torres A. Pharmacotherapy for hospital-acquired pneumonia. Expert Opin Pharmacother. 2014 Apr;15(6):775–786.
   PubMed Web of Science ®Google Scholar
• Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36:1089–1096.
   PubMed Web of Science ®Google Scholar
• Chahine EB, Ferrill MJ. Poulakos MN. Doripenem: a new carbapenem antibiotic. Am J Health Syst Pharm. 2010;67(23):2015–2024.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem–cilastatin for ventilator-associated pneumonia. Crit Care. 2012;16:R218.
   PubMed Web of Science ®Google Scholar
• [cited 2014 Jun 3]. Available from: www.fda.gov/Drugs/DrugSafety/ucm387971.htm‎
   Google Scholar
• Liapikou A, Cilloniz C, Mensa J, et al. New antimicrobial approaches to gram positive respiratory infections. Pulm Pharmacol Ther. 2015 Jun;32:137–143.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 1;59(1):51–61. Apr 9
   PubMed Web of Science ®Google Scholar
• Lagace Wiens PR, Rubinstein E. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):789e99.
   Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52:31–40.
   PubMed Web of Science ®Google Scholar
• Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014;58:2030–2037.
   PubMed Web of Science ®Google Scholar
• [cited 2013 Jun 21]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm358209.htm
   Google Scholar
• Freire AT, Melnyk V., Kim M. J, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140–151.
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54:1699–1709.
   PubMed Web of Science ®Google Scholar
• Chuang Y-C, Cheng C. Y. Sheng W. H, et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14(1):102.
   PubMed Web of Science ®Google Scholar
• Paladino JA, Sunderlin JL, Forrest A, et al. Characterization of the onset and consequences of pneumonia due to fluoroquinolone- susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2003;52:457–463.
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357–363.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America: America. The 10 × ′20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1081–1083.
   PubMed Web of Science ®Google Scholar
• Chiu SK, Wu TL, Chuang YC, et al. National surveillance study on carbapenems non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One. 2013;8:e69428.
   PubMed Web of Science ®Google Scholar
• Lemaire S, Van Bambeke F, Appelbaum PC, et al. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother. 2009;64:1035e43.
   Web of Science ®Google Scholar
• Keel RA, Tessier PR, Crandon JL, et al. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents and Chemother. 2012;56(8):4403–4407.
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs. linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13;309(6):559e69.
   Web of Science ®Google Scholar
• FDA approves new antibacterial drug Avycaz [Internet]. 2015 Feb 25. [cited 2015 Mar 20]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm
   Google Scholar
• Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from US medical centers in 2012. Antimicrob Agents Chemother. 2014;58(3):1684–1692.
   PubMed Web of Science ®Google Scholar
• Lahiri SD, Mangani S, Durand-Reville T, et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob Agents Chemother. 2013;57(6):2496–2505.
   PubMed Web of Science ®Google Scholar
• Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014;9:13–25.
   PubMedGoogle Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013 Feb;73(2):159–177.
   PubMed Web of Science ®Google Scholar
• Actavis plc. Actavis Receives U.S. FDA Approval for AVYCAZ™ (CEFTAZIDIME-AVIBACTAM). 2015 Feb 25. cited 2015 Mar 3. Available from: http://www.prnewswire.com/news-releases /actavis-receives-us-fdaapproval- for-avycaz-ceftazidime-avibactam-300041592.html
   Google Scholar
• AstraZeneca. A study comparing ceftazidime-avibactam versus meropenem in hospitalized adults with nosocomial pneumonia. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01808092. NLM identifier: NCT01808092.
   Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014 Jan;74(1):31–51.
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Farrell DJ, et al. Antimicrobial activity of CXA- 101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011;55:2390–2394.
   PubMed Web of Science ®Google Scholar
• Cubist Pharmaceuticals Holdings LLC. Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia. [cited 2015 Feb 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT01853982. NLM identifier: NCT01853982.
   Google Scholar
• Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrob Agents Chemother. 2009 May;53(5):2171–2175.
   PubMed Web of Science ®Google Scholar
• Andrews J, Honeybourne D, Ashby J, et al. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother. 2007;60:677–680.
   PubMed Web of Science ®Google Scholar
• Kohlhoff SA, Sharma R. Iclaprim. ExpertOpin Investig Drugs. 2007;16:1441–1448.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Hawser S. Activity of iclaprim against Legionella pneumophila. J Antimicrob Chemother. 2007;60:905–906.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014 Jul 3;15(10):1351–1370.
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M. Daikos GL. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 2012;24(4):191–194.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next- generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10:459–473.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov NCT01970371 [cited 2013 Oct 23]. Available from: www.clinicaltrials.gov/ct2/show/NCT01970371
   Google Scholar
• [cited 2014 Jun 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02168946
   Google Scholar
• Kollef MH, Hamilton CW. Montgomery AB. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis. 2013;26:538–544.
   PubMed Web of Science ®Google Scholar
• Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated trachea-bronchitis in the intensive care unit. Crit Care Med. 2008;36:2008–2013.
   PubMed Web of Science ®Google Scholar
• Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012;117(6):1335–1347.
   PubMed Web of Science ®Google Scholar
• Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomized trial. Ann Intensive Care. 2016 Dec;6(1):26.
   PubMed Web of Science ®Google Scholar
• Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med. 2015 Mar;43(3):527–533.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 2012 Mar 1;54(5):670–680.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008 Apr 15;46(8):1157–1164.
   PubMed Web of Science ®Google Scholar
• Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther. 2008 Feb;6(1):39–49.
   PubMed Web of Science ®Google Scholar
• [cited 2009 Mar 25]. Available from: http://www.wikinvest.com/stock/Ceragenix_Pharmaceuticals_(CGXP)/Ceragenins
   Google Scholar
• Lazar H, Horn MP, Zuercher AW, et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother. 2009;53(8):3442–3446.
   PubMed Web of Science ®Google Scholar
• Le Berre R, Nguyen S, Nowak E, et al. Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia. Crit Care Med. 2011;39:2113–2120.
   PubMed Web of Science ®Google Scholar
• Luyt CE, Brechot N, Combes A, et al. Delivering antibiotics to the lungs of patients with ventilator associated pneumonia: an update. Expert Rev Anti Infect Ther. 2013;11:511–521.
   PubMed Web of Science ®Google Scholar
• Taneja N, Kaur H. Insights into newer antimicrobial agents against gram-negative bacteria. Microbiol Insights. 2016 Mar;20(9):9–19.
   Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072–1083.
   PubMed Web of Science ®Google Scholar